Skip to content

Liver Glycogen Dynamics

Liver Glycogen Dynamics and Substrate Oxidation in Lean Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04510155
Acronym
LGD
Enrollment
10
Registered
2020-08-12
Start date
2020-09-11
Completion date
2021-05-21
Last updated
2021-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Glycogen

Brief summary

The purpose of this study is to investigate the effect of prolonged overnight fasting in the hepatic glycogen stores

Interventions

Subjects will adhere to overnight fasting protocol for 1 day

Sponsors

Maastricht University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants are able to provide signed and dated written informed consent prior to any study specific procedures * Caucasian (people will be excluded when having a ≥50% racial African/Asian background) * Participants should have suitable veins for cannulation or repeated venipuncture * Women are post-menopausal (defined as at least 1 year post cessation of menses) * Men and women aged ≥ 45 and ≤ 75 years at the start of the study * Body mass index (BMI) 18.5 - 25 kg/m2 * Stable dietary habits (no weight loss or gain \>3kg in the past 3 months) * Sedentary lifestyle (not more than 3 hours of vigorous sports per week)

Exclusion criteria

* Type 2 Diabetes Mellitus * Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other) * Any contraindication for MRI scanning * Alcohol consumption of \>2 servings per day * Regular smoking * No use of medication interfering with investigated study parameters (as determined by responsible physician) * Participants who do not want to be informed about unexpected medical findings, or do not wish that their physician

Design outcomes

Primary

MeasureTime frameDescription
Hepatic glycogen content1 hourMeasured with 13C-MRS

Secondary

MeasureTime frameDescription
Substrate oxidation14 hoursMeasured as RQ

Other

MeasureTime frameDescription
Hepatic fat oxidation5 hoursmeasured as plasma BHB levels
Liver volume5 minutesMeasured with MRI
Intrahepatic fat content and composition (1H-MRS)30 minutesMeasured with 1H-MRS
Plasma metabolites related to energy metabolism5 hoursmeasured in plasma samples
Body composition5 minutesfat mass/fat free mass measured with BodPod
Substrate oxidation30 minutesmeasured with indirect calorimetry
De novo lipogenesis (DNL)20 hoursmeasured as percentage of palmitate in VLDL-TG originating from DNL

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026